Sarka Svobodova1,2, Marie Karlikova1, Ondrej Topolcan1, Ladislav Pecen1, Martina Pestova1, Otto Kott3, Vladislav Treska4, David Slouka1, Radek Kucera5. 1. Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic. 2. Third Internal Medicine Department and First Medical Faculty, Charles University, Prague, Czech Republic. 3. Faculty of Health Care Studies, University of West Bohemia, Pilsen, Czech Republic. 4. Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic. 5. Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic kucerar@fnplzen.cz.
Abstract
AIM: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. MATERIALS AND METHODS: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). RESULTS: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. CONCLUSION: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers. Copyright
AIM: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. MATERIALS AND METHODS: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). RESULTS: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. CONCLUSION: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers. Copyright
Authors: Henry L Y Chan; Arndt Vogel; Thomas Berg; Enrico N De Toni; Masatoshi Kudo; Jörg Trojan; Anja Eiblmaier; Hanns-Georg Klein; Johannes Kolja Hegel; Ashish Sharma; Kairat Madin; Vinzent Rolny; Marcus-Rene Lisy; Teerha Piratvisuth Journal: JGH Open Date: 2022-05-07